AUGUSTUS
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
Paziente / Popolazione Intervento / Esposizione Confronto Esito
In 4,614 patients with AF and recent ACS or PCI, apixaban without aspirin reduced major or clinically relevant bleeding compared with warfarin-based triple therapy.
N
4614
Disegno
2×2 factorial RCT
Esito
Major or clinically relevant non-major bleeding
Rilevanza
1
RisultatoApixaban vs warfarin HR 0.69; aspirin vs placebo HR 1.89 for bleeding.
Lopes RD, et al. N Engl J Med. 2019;380(16):1509-1524. 10.1056/NEJMoa1817083
Discussione e critica
Established apixaban plus a P2Y12 inhibitor without aspirin as the default. Triple therapy is now limited to roughly the first week after PCI.